Core Viewpoint - Recent earnings forecasts from listed vitamin companies indicate a mixed outlook for 2025, with Nengte Technology and Brothers Technology expecting profits, while Guangji Pharmaceutical anticipates significant losses [1][11]. Group 1: Nengte Technology - Nengte Technology forecasts a net profit of 200 million to 250 million yuan for 2025, a significant recovery from a loss of 588 million yuan in the previous year [2][11]. - The increase in profit is primarily driven by a substantial growth in the vitamin E business, which is expected to contribute no less than 660 million yuan [2][11]. - However, the pharmaceutical intermediates business underperformed, with lower-than-expected sales of Montelukast sodium intermediates and ongoing price competition in the market for Rosuvastatin intermediates, leading to a proposed goodwill impairment of up to 260 million yuan [2][12]. Group 2: Brothers Technology - Brothers Technology anticipates a net profit of 85 million to 110 million yuan for 2025, representing a year-on-year growth of 108.26% to 169.52% [4][11]. - The expected growth is attributed to price increases in certain vitamin products, higher production and sales volumes of phenol derivatives, and a reduction in costs for some products [4][11]. Group 3: Guangji Pharmaceutical - Guangji Pharmaceutical projects a net loss of 399 million to 518 million yuan for 2025, compared to a loss of 295 million yuan in the previous year [5][11]. - The company cites intensified market competition as a key factor, resulting in prolonged low sales prices for its main products and underperformance in capacity utilization and overall operational results [5][11].

Market Performance - The new materials sector experienced a decline this week, with the new materials index falling by 5.29%, underperforming the ChiNext index which decreased by 5.19% [1][4] - Over the past five trading days, the synthetic biology index dropped by 3.13%, semiconductor materials by 3.60%, electronic chemicals by 3.77%, biodegradable plastics by 0.90%, industrial gases by 3.96%, and battery chemicals by 4.89% [1][9] Price Tracking - Amino acids prices showed the following changes: valine remained at 14,050 CNY/ton, arginine increased by 2.64% to 21,400 CNY/ton, tryptophan rose by 1.27% to 31,900 CNY/ton, and methionine increased by 2.82% to 18,200 CNY/ton [2] - Prices for biodegradable materials remained stable, with PLA (FY201 injection grade) at 17,800 CNY/ton and PBS at 17,000 CNY/ton [2] - Vitamin A decreased by 1.60% to 61,500 CNY/ton, while other vitamins remained unchanged [2] Investment Recommendations - SpaceX plans to establish a satellite constellation of up to 1 million satellites, significantly increasing demand for upstream raw materials, particularly lightweight and cable materials [3] - Companies to watch in lightweight materials include Times New Material, Jilin Chemical Fiber, Zhongfu Shenying, Guangwei Composites, and Heshun Technology; for cable materials, focus on Pulit and Panyam Micro透 [3]

IPO Dynamics - Muyuan Foods plans to launch its Hong Kong IPO as early as January 29, aiming to raise up to $1.5 billion (approximately HKD 11.7 billion) and is expected to list on February 6 [3] - The funds raised will be used for overseas expansion, smart farming R&D, and debt repayment, potentially creating an "A+H" dual financing platform to strengthen capital during the pig cycle downturn [3] Acquisitions & Sales - JBB Builders is in discussions to acquire 100% equity of Chengdu Jianfu Convenience Store Management Co., which operates 65 direct stores and 30 franchised stores, aiming to enter the rapidly growing Chinese retail market [5] - Unilever has signed an agreement to sell its home care business in Colombia and Ecuador to Alicorp, which includes established local brands like Fab and 3D [8] - General Mills announced the sale of its Muir Glen organic tomato brand to Violet Foods, allowing General Mills to focus on core brands like Cheerios and Progresso [12] - Vitabiotics, a UK vitamin company, is attracting bids from private equity firms including Bain Capital and Blackstone, with a potential valuation of around £900 million (approximately RMB 8.6 billion) [15] Corporate Restructuring - MTG Corporation announced the dissolution of its wholly-owned subsidiary in Shanghai, which has been operating since 2013 and responsible for sales in the Chinese market, due to continuous losses [18][19] - On (昂跑) appointed Frank Sluis as the new CFO, expected to drive sales growth of at least 34% year-on-year for the fiscal year 2025 [21] - BVLGARI appointed Domenico Giampà as the director of its fragrance business, focusing on commercial strategy and growth in high-end fragrance segments [24] - L'OCCITANE appointed Mark Edington as the general manager for travel retail in EMEA and the Americas, leveraging his extensive experience to boost travel retail performance [27] - A2 Milk Company expanded the responsibilities of its Greater China CEO, allowing for better local management of market strategies [30]

Investment Rating - The report rates the chemical industry as "Outperform" [2] Core Views - The report highlights the rise in international oil prices and the increase in prices of disperse dyes and vitamin E, suggesting a focus on undervalued industry leaders and the impact of "anti-involution" on supply in related sub-industries [2][11] - It emphasizes the importance of strong downstream demand and the growing significance of self-sufficiency in electronic materials companies [2][11] Industry Dynamics - In the week of January 25 to February 1, 2026, among 100 tracked chemical products, 50 saw price increases, 22 saw declines, and 28 remained stable. Overall, 61% of products had month-on-month price increases, while 30% saw declines [11][36] - The average price of WTI crude oil rose to $65.21 per barrel, with a weekly increase of 6.78%, while Brent crude oil reached $70.69 per barrel, up 7.30% [11][37] - The report notes that the average price of disperse black ECT300% increased by 5.56% to 19 yuan/kg, and the average price of vitamin E rose by 1.9% to 53.5 yuan/kg [38][39] Investment Recommendations - The report recommends focusing on undervalued industry leaders, the effects of "anti-involution" on supply in relevant sub-industries, and companies in electronic materials benefiting from strong downstream demand [11][14] - Long-term investment themes include traditional chemical leaders showing resilience, sectors benefiting from "anti-involution," and companies in new materials with significant growth potential [11][14] - Specific stock recommendations include China Petroleum, China National Offshore Oil Corporation, China Petrochemical Corporation, and Zhejiang Longsheng among others [11][14]

Core Viewpoint - The company held its first extraordinary board meeting of 2026, where several key resolutions were passed, including the approval of bank credit limits and related party transactions for the year [1][2][4][6][10]. Group 1: Bank Credit and Financing - The board approved a total bank credit limit of 5.771 billion yuan for 2026, with 1.960 billion yuan allocated to the headquarters and 3.811 billion yuan to subsidiaries [2]. - Additionally, the company and its subsidiaries will apply for project financing credit totaling 1.145 billion yuan, with 740 million yuan for the headquarters and 405 million yuan for subsidiaries [2]. Group 2: Related Party Transactions - The board approved ongoing sales of poultry vaccines and veterinary medicines to Shandong Zhongxin Food Group Co., Ltd., with an estimated transaction amount not exceeding 24 million yuan for 2026 [4][14]. - The company will also continue to purchase production raw materials from Xiamen Jindawei Group Co., Ltd., with an estimated transaction amount not exceeding 31 million yuan for 2026 [6][16]. Group 3: Internal Audit and Salary Budget - The board approved the internal audit plan for 2026 [8][9]. - The board also approved the salary budget for 2025, along with the evaluation report for the total salary for 2024 [10][11]. Group 4: Upcoming Shareholder Meeting - The board agreed to convene the second extraordinary shareholder meeting of 2026 to discuss additional matters requiring shareholder approval [11]. Group 5: Performance Forecast - The company anticipates a net profit attributable to shareholders of 148.59 million to 192.29 million yuan for 2025, representing an increase of 77.70 million to 121.41 million yuan compared to the previous year, which is a year-on-year increase of 109.62% to 171.27% [32][33]. - However, the net profit after deducting non-recurring gains and losses is expected to be between 16.90 million and 23.24 million yuan, a decrease of 38.90 million to 45.24 million yuan compared to the previous year, reflecting a year-on-year decrease of 62.60% to 72.80% [33]. Group 6: Reasons for Performance Increase - The increase in net profit is attributed to gains from investments, including the subscription of convertible bonds issued by Xiamen Jindawei Group and the abandonment of the right of first refusal for shares in Zhongpu Biopharmaceutical Co., Ltd. [37]. - The company has also optimized its marketing structure and product development to enhance operational efficiency [37].

Core Viewpoint - Recent changes in the regulatory focus for IPO applications in the semiconductor sector indicate a shift towards evaluating core technological capabilities and operational stability, rather than just fundraising amounts and project plans [1] Group 1: IPO Applications - Two semiconductor companies have withdrawn their IPO applications from the Sci-Tech Innovation Board [2] - The regulatory review process is becoming increasingly stringent, with a focus on the details of the application process [1][2] Group 2: Market Dynamics - The true direction of the market is determined by the real attitude of capital, rather than external policies or news [1] - Quantitative data can reveal hidden behaviors of capital, allowing for a clearer understanding of market dynamics [1][5] Group 3: Institutional Participation - The "institutional inventory" metric reflects whether large institutional funds are actively participating in a stock's trading, indicating its long-term value [5][9] - Stocks with active institutional inventory tend to perform better, as they have been recognized by institutions prior to market hype [7][9] Group 4: Investment Logic - The reliance on subjective judgment and emotional responses in investment decisions can lead to poor outcomes; objective, quantifiable data should guide decisions instead [10] - A shift in understanding the importance of capital's attitude over external news can enhance investment strategies and decision-making [10]

Core Viewpoint - The Federal Reserve's announcement of over $200 billion in "reserve management purchases" is seen as a signal of market changes, but the real determinant of stock price movements is the active trading behavior of institutional investors rather than the news itself [1][9]. Group 1: Institutional Trading Behavior - The significant price increase of Vitamin D3 from 56 yuan/kg to 265 yuan/kg (a 360% increase) did not uniformly benefit all related stocks, with 23 out of 73 stocks declining, highlighting that institutional trading activity is crucial for stock price movements [4][5]. - Institutional investors' early engagement in trading can lead to substantial stock price increases even before positive news is released, as demonstrated by a specific vitamin stock that saw its price double after institutions began trading before the price hike announcement [5][7]. - Conversely, stocks that did not see early institutional activity failed to benefit from subsequent positive news, with one stock's price halving despite the announcement of favorable conditions [7][9]. Group 2: Importance of Monitoring Institutional Activity - The $200 billion from the Federal Reserve serves as a market signal, but the focus should be on whether institutions are actively trading the stocks held [9]. - A case study illustrates that an investor lost 30% by purchasing a stock without institutional activity despite positive news, while another stock with active institutional trading yielded a 20% gain, emphasizing the importance of monitoring institutional engagement [9]. - The market does not always react positively to good news or negatively to bad news; the key is to identify stocks with active institutional trading, which can be facilitated by data tools that reveal trading characteristics [9].

Investment Rating - The report indicates a positive investment outlook for the basic chemical industry, with significant growth in specific sub-sectors such as TDI and synthetic resins [1][2]. Core Insights - The TDI export volume reached a historical high in November, with 56,500 tons exported, significantly exceeding previous years' totals, and is projected to continue growing [2]. - The China Synthetic Resin Association has called for the regulation of the polyoxymethylene industry to address structural supply-demand imbalances, with projected production capacity reaching 1.51 million tons per year against a demand of only 950,000 tons by 2025 [2]. - The chemical sector overall has shown strong performance, with the CITIC Basic Chemical Index rising by 5.41% this week, outperforming other indices [1][10]. Market Performance - The Shanghai Composite Index increased by 1.88%, while the ChiNext Index rose by 3.9%, indicating a bullish trend in the market [1][10]. - The top-performing sub-sectors in the chemical industry this week included membrane materials (12.18%), synthetic resins (8.23%), and phosphate fertilizers (6.5%) [1][13]. Sub-sector Summaries TDI - November TDI exports reached 56,500 tons, with a cumulative export of 506,300 tons from January to November, marking a 56.2% year-on-year increase [2]. - The average export price for TDI in October was $1,527 per ton, with a total export value of $67.1 million [2]. Polyoxymethylene - The industry faces challenges due to a projected capacity of 1.51 million tons against a demand of only 950,000 tons, leading to potential oversupply issues [2]. Tires - Domestic tire manufacturers are becoming increasingly competitive, with a focus on growth opportunities in the tire sector [2]. Phosphate Chemicals - The phosphate chemical sector is expected to benefit from environmental policies limiting supply, coupled with increasing demand from the new energy sector [4]. Vitamins - The market for vitamins is experiencing supply disruptions, particularly for Vitamin A and E, due to unforeseen circumstances affecting production [5].

Core Viewpoint - The report from Huazhong Securities highlights the peak of domestic silicon production capacity, the exit of overseas manufacturers, and the potential recovery of the polyester chain's prosperity due to concentrated production capacity in the polyester filament sector [1][3]. Group 1: Industry Trends - Domestic silicon production capacity has reached its peak, while leading companies are driving industry recovery as overseas manufacturers continue to exit [1][3]. - The PTA production capacity expansion is nearing its end, leading to a concentration in polyester filament production capacity, which is expected to improve the prosperity of the polyester chain [1][3]. - The price of caprolactam has dropped to a low point, prompting the industry to initiate self-driven anti-involution measures [3]. - The raw material price index has rebounded after hitting a bottom, with frequent safety incidents causing significant risks to the global supply chain of key pesticides [3]. - The price of spandex has remained below the cost line, leading to widespread industry losses, but a slowdown in new capacity releases may optimize the supply structure and drive price recovery [3]. - The vitamin market is expected to see significant price increases in 2024 due to a tightening global supply [3]. Group 2: Investment Opportunities - The report emphasizes two main investment themes: anti-involution and domestic substitution, particularly in the context of global macroeconomic uncertainties and a slowdown in chemical capital expenditures [2][4]. - The biobased materials sector is receiving strong support from national policies, with companies accelerating technological breakthroughs and industrialization [4][6]. - The lubricating oil additive sector is witnessing rapid technological advancements among domestic companies, with several high-end products achieving international certification [4][6]. - The electronic ceramics market is seeing strong demand driven by AI and automotive sectors, with domestic manufacturers making breakthroughs in MLCC production [4][6]. - The exit of 3M from the fluorinated liquids market is reshaping the competitive landscape, with domestic manufacturers expected to increase their market share [4][6]. - The explosive growth of AI servers is driving demand for electronic-grade polyphenylene ether, with domestic manufacturers achieving technological breakthroughs and entering key supply chains [4][6].

Investment Strategy Overview - The report emphasizes two main investment themes for the chemical industry: anti-involution policies and domestic substitution, which are expected to drive recovery and growth in the sector [4][5][6] Anti-Involution and Cycle Recovery - The report suggests that the chemical industry is at a turning point, with anti-involution measures leading to a recovery in the cycle. Key areas include the peak of new capacity in organic silicon, the end of PTA capacity expansion, and a rebound in prices for certain chemicals due to supply chain disruptions [4][5] - The China Chemical Product Price Index (CCPI) has decreased significantly, dropping to 3865 points by November 30, 2025, down 16.37% from early 2024 and 10.71% from the beginning of 2025 [4][20] Domestic Substitution as a Growth Driver - Domestic substitution is highlighted as a key growth driver, with significant support from national policies for bio-based materials and advancements in technology leading to a more robust domestic supply chain [4][6] - The report identifies several companies positioned to benefit from these trends, including KaiSai Bio and RuiFeng New Materials, which are making strides in bio-based materials and lubricant additives, respectively [5][6] Market Dynamics and Price Recovery - The report notes that while the chemical market is experiencing a downturn, certain segments are expected to see price recovery due to improved supply-demand dynamics and reduced capacity expansion [4][22] - Specific chemical products have shown varied price movements, with some experiencing significant declines while others are stabilizing or recovering [22] Manufacturing Sector Recovery - The manufacturing sector is showing signs of recovery, which is anticipated to support the chemical industry. The report mentions that the real estate market is stabilizing, and automotive production has increased, indicating a potential uptick in demand for chemical products [25][33] Capital Expenditure Trends - Capital expenditure growth in the chemical industry is slowing, with a notable decline in new projects. The report indicates that the total construction in progress for the chemical sector was 327.57 billion yuan in Q3 2025, down 17.64% year-on-year [34][39] Inventory and Consumption Trends - High inventory levels in the chemical sector are being addressed as consumer demand begins to recover. The report suggests that the inventory-to-revenue ratio for the basic chemical industry was 0.62 in Q3 2025, indicating a slight increase from the previous year [41][42] Profitability and Financial Performance - The report highlights a recovery in profitability for the chemical industry, with gross margins and return on equity (ROE) showing improvement in Q3 2025 compared to previous periods [56][60] - Specific sub-sectors, such as agrochemicals and fluorochemicals, have demonstrated significant profit growth, with some exceeding 100% year-on-year increases [55][56]